drugset / Trial / NCT01054443
A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study was to assess the efficacy of 3 dose levels of lusutrombopag (0.5 mg, 0.75 mg, and 1.0 mg) and placebo on platelet count.
Timeline
- Start
- 2010-03-18
- Primary completion
- 2010-11-24
- Completion
- 2010-11-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lusutrombopag | Small molecule | 0.5 mg | Oral |
| Subject | Lusutrombopag | Small molecule | 0.75 mg | Oral |
| Subject | Lusutrombopag | Small molecule | 1 mg | Oral |